35970-31-1

Basic information

• Product Name: 2-AMINO-1-(2,3-DIHYDRO-BENZO[1,4]DIOXIN-6-YL)-ETHANONE
• Synonyms: 2-AMINO-1-(2,3-DIHYDRO-BENZO[1,4]DIOXIN-6-YL)-ETHANONE;2-aMino-1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethan-1- one hydrochloride;2-Amino-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethanone hydrochloride;2-Amino-1-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-ethanone hydrochloride;2-amino-1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethanone hydrochloride
• CAS NO: 35970-31-1
• Molecular Formula: C10H12ClNO3
• Molecular Weight: 229.66
• Mol File: 35970-31-1.mol

Chemical Properties

• Melting Point: 247-248 °C(Solv: water (7732-18-5); methanol (67-56-1))
• Appearance: /
• CAS DataBase Reference: 2-AMINO-1-(2,3-DIHYDRO-BENZO[1,4]DIOXIN-6-YL)-ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-1-(2,3-DIHYDRO-BENZO[1,4]DIOXIN-6-YL)-ETHANONE(35970-31-1)
• EPA Substance Registry System: 2-AMINO-1-(2,3-DIHYDRO-BENZO[1,4]DIOXIN-6-YL)-ETHANONE(35970-31-1)

Safety Data

• Hazardous Substances Data: 35970-31-1(Hazardous Substances Data)

Usage

Also known as

6-Amino-2,3-dihydro-2,3-dioxo-1,3-benzodioxol-5-ol
Used in the pharmaceutical industry as a building block for the synthesis of various drugs and drug candidates
Potential therapeutic applications in the treatment of conditions such as cancer, inflammation, and infectious diseases
Used in research laboratories for the development of new pharmaceutical compounds
Used as a tool for studying biological processes

Upstream product

• 4629-54-3 2-bromo-1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethanone 
• 2879-20-1 1,4-benzodioxan-6-yl methyl ketone 
• 93439-37-3 2-chloro-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethan-1-one 

Downstream Products

• 491833-29-5 (1R,2R)-octanoic acid [2-(2',3'-dihydro-benzo[1,4]dioxin-6'-yl)-2-hydroxy-1-pyrrolidin-1-ylmethyl-ethyl]-amide 

Relevant articles and documents

A novel method for preparing Eligulstat through chiral resolution

Eliglustat is a ceramide glucosyltransferase inhibitor work as first line oral therapy for adults with Gaucher disease type 1 (a rare disease) at present. Although the eliglustat in enantiomerically pure forms is obtained by asymmetric syntheses, the reported methods suffer from many limits when it comes to industrial applications. Therefore, the preparation of a racemic mixture followed by resolution can still be a viable and straightforward alternative, especially when it could be adapted to large scale. Herein, we developed an effective and practical synthetic route to prepare stereoisomers mixture of eliglustat, and a novel chiral resolution method to prepare eliglustat. Using 1,1′-Binaphthyl-2,2′-diyl -hydrogenphosphate (BNDHP) as resolution reagent, optical pure eliglustat (e.e. >99%, 13.97% total yield) could be obtained after recrystallization.

PROCESS FOR PREPARATION OF ELIGLUSTAT HEMITARTRATE AND INTERMEDIATES THEREOF

Process for preparation of eliglustat hemitartrate and intermediates thereof Processes for preparation of eliglustat hemitartrate and intermediates thereof are provided. A stable amorphous form of eliglustat hemitartrate pharmaceutical compositions includ

Amino ceramide-like compounds and therapeutic methods of use

Novel amino ceramide-like compounds are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer syn